Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

Xenobiotica

Volumn 36, Issue 12, 2006, Pages 1239-1258

  Mustafa, S ^a   Venkatesh, P ^a   Pasha, K ^a   Mullangi, R ^a   Srinivas, N R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Acute renal failure; Adenosine A1 antagonists; Pharmacokinetics; Rats; Topotecan; Uranyl nitrate

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; TOPOTECAN; URANYL NITRATE; ZEXATE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; KIDNEY CLEARANCE; LIVER MICROSOME; NONHUMAN; RAT; URINARY EXCRETION;

ANIMALS; CAFFEINE; DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, ACUTE; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1; TOPOTECAN; URANYL NITRATE; XANTHINES; XENOBIOTICS;

EID: 33845618911     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600839385     Document Type: Article

References (49)

1. Ahn CY, Kim EJ, Lee I, Kwon JW, Kim WB, Kim SG, Lee MG. 2003. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Journal of Pharmaceutical Sciences 92:1604-1613.
2. Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. 2004. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. Journal of Pharmaceutical Sciences 93:2353-2363.
3. Bellomo R, May C, Wan L. 2004. Acute renal failure and sepsis. New England Journal of Medicine 351:2347-2349.
4. Bradford MA. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248-254.
5. Brenner BM, Lazarus JM. 1992. Acute renal failure. 3rd ed. New York, NY: Churchill Livingstone. pp 359-360.
6. Chung HC, Kim SH, Lee MG, Kim SG. 2002. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by renal failure. Drug Metabolism and Disposition 30:739-746.
7. Chung WS, Kim EJ, Lee I, Kim SG, Lee MG, Kim SH. 2003. Effects of recombinant growth hormone on the pharmacokinetics of chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sciences 73:253-263.
8. Churchill PC, Bidani AK. 1982. Hypothesis: Adenosine mediates hemodynamic changes in renal failure. Medical Hypotheses 8:275-285.
9. Creemers GJ, Lund B, Verweij J. 1994. New drugs: Topoisomerase I inhibitors: Topotecan and irenotecan. Cancer Treatment Reviews 20:73-96.
10. Dennis MJ, Beijnen JH, Grochow LB, Van Warmerdam LJ. 1997. An overview of the clinical pharmacology of topotecan. Seminars in Oncology 24:S5-12-S5-18.
11. Engineer MS, Ho DH, Bodey Sr GP. 1981. Comparison of vancomycin disposition in rats with normal and abnormal renal functions. Antimicrobial Agents and Chemotherapy 20:718-722.
12. Fruncillo RJ, Swanson BN, Bernhard R, Marchion C, Ferguson RK. 1986. Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. Journal Pharmaceutical Sciences 75(2):150-154.
13. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. 1996. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. Journal of Clinical Oncology 14:1504-1511.
14. Gibaldi M, Perrier D. 1982. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker.
15. Gibson TP. 1986. Applied pharmacokinetics. 2nd ed. Washington, DC: Applied Therapeutics. pp 83-115.
16. Gulyassy PF, Depner TA. 1983. Impaired binding of drugs and endogenous ligands in renal diseases. American Journal of Kidney Diseases 2:578-601.
17. Gupta M, Fujimori A, Tamhane AC. 1995. Eukaryotic DNA topoisomerases I. Biochimica Biophysics Acta 1262:1-14.
18. Henry J.B. 1991. Clinical diagnosis and management by laboratory methods. 18th ed. Philadelphia, PA: W. B. Saunders. pp 120-122.
19. Iven H, Brasch H. 1986. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemotherapy and Pharmacology 17:218-222.
20. Kim SH, Shim HJ, Kim WB, Lee MG. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrobial Agents Chemotherapy 42:1217-1221.
21. Lee AK, Lee JH, Kwon JW, Kim WB, Kim SG, Kim SH, Lee MG. 2004. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharmaceutics and Drug Disposition 25:273-282.
22. Lee W, Kim RB. 2004. Transporters and renal drug elimination. Annual Reviews in Pharmacology and Toxicology 44:137-166.
23. Lee YH, Lee MH, Shim CK. 1992. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharmaceutical Research 9:1599-1606.
24. Lindup WE, Henderson SJ, Barker CE. 1991. In: Belpaire F, Bogaert M, Tillement JP, Verbeeck E, editors. Plasma binding of drug and its consequence. Ghent: Academic Press. pp 103-120.
25. Lindup WE. 1987. In: Bridges JW, Chasseaud LF, Gibson CG, editors. Progress in drug metabolism. Vol. 10. London: Taylor & Francis. pp 141-185.
26. Liu JH, Malone RS, Stallings H, Smith PC. 1996. Influence of renal failure on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins. Journal of Pharmacology and Experimental Therapeutics 278:277-283.
27. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. 1995. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical Pharmacology and Therapeutics 58:641-649.
28. Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. 2003. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metabolism and Disposition 31:776-784.
29. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen T, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB. 1996a. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. Journal of National Cancer Institute 88:817-824.
30. O'Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen T, Sartorius S, Grochow LB. 1996b. Phase I and pharmacologic study of topotecan in patients with impaired renal function. Journal of Clinical Oncology 14:3062-3073.
31. Park JM, Moon CH, Lee MG. 1996. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Research Communications in Molecular Pathology and Pharmacology 93:353-362.
32. Park KJ, Yoon WH, Kim SH, Shin WG, Lee MG. 1998. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharmaceutics and Drug Disposition 19:141-146.
33. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 6:566-573.
34. Platzer P, Schaden S, Thalhammer T, Hamilton G, Rosenberg B, Silgoner I, Jager W. 1998. Biotransformation of topotecan in the isolated perfused rat liver: Identification of three novel metabolites. Anticancer Research 18:2695-2700.
35. Potmesil M. 1994. Camptothecins: From bench research to hospital wards. Cancer Research 54:1431-1439.
36. Rao MNVS, Biju B, Ansar AK, Mujeeb S, Ramesh M, Srinivas NR. 2003. Open access generic method for continuous determination of major human CYP 450 substrates/metabolites and its application in drug metabolism studies. Xenobiotica 12:1233-1245.
37. Sakai T, Maruyama T, Imamura H, Shimada H, Otagiri M. 1996. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. Journal of Pharmacology and Experimental Therapeutics 278:786-792.
38. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J. 1996. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. British Journal of Cancer 73:1268-1271.
39. Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfar S. 1995. The pharmacokinetics of losartan in renal insufficiency. Journal of Hypertension 13(Suppl. 1):S49-S52.
40. Slichenmyer WJ, Chen TL, Donehower RC, Sartorius S, Rowinsky E, Shifflett C, Bowling MK, Grochow L. 1994. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction (abstract). Proceedings of Annual Meeting of American Society of Clinical Oncology 13: A363.
41. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. 1994. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts haematologic toxicity. Journal of Clinical Oncology 12:1946-1954.
42. Tagawa H, Sugimoto T, Saito H, Nishio K. 1995. The hypotensive effect and pharmacokinetics of MK-954 (losartan potassium) in hemodialysis patients with high blood pressure. Japan Journal of Clinical Dialysis 11:247-264.
43. Underberg WJ, Goossen RM, Smith BR, Beijnen JH. 1990. Equilibrium kinetics of the new experimental antitumour compound SK&F 104864-A in aqueous solution. Journal of Pharmaceutical Biomedical Analysis 8:681-683.
44. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology 409:31-36.
45. Wall ME, Wani MC. 1977. Antineoplastic agents from plants. Annual Review of Pharmacology and Toxicology 17:117-132.
46. Yoshitani T, Yagi H, Inotsume N, Yasuhara M. 2002. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biological and Pharmaceutical Bulletin 8:1077-1083.
47. Yu SY, Chung HC, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. 2002. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. Journal of Pharmacy and Pharmacology 54:1687-1692.
48. Zamboni WC, Heideman RL, Meyer WH, Gajjar AJ, Crom WR, Stewart CF. 1996. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function (abstract). Proceedings of the American Society for Clinical Oncology 15: 371.
49. Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo S, Stewart CF. 1998. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. Journal of Pharmacology and Experimental Therapeutics 284:89-94.